Fluvoxamine–Mirtazapine Combination for Depression
The combination of fluvoxamine (Luvox) and mirtazapine (Remeron) has been used clinically for treatment-refractory depression strategies, but it is not a standard, depression-specific regimen with a dedicated evidence-based dosing schedule. (pmc.ncbi.nlm.nih.gov) Fluvoxamine can increase mirtazapine exposure, which can increase the likelihood of adverse effects and require closer safety monitoring. (pmc.ncbi.nlm.nih.gov)
Medication Selection Algorithm
When the combination is used, the same antidepressant safety and interaction principles apply for both agents.
- Fluvoxamine (SSRI; CYP inhibitor) is selected when serotonergic augmentation is desired. (accessdata.fda.gov)
- Mirtazapine (tetracyclic antidepressant) is selected when noradrenergic/serotonergic mechanisms with sedating properties are desired. (dailymed.nlm.nih.gov)
- Combination use should be limited to cases where benefits outweigh risks from pharmacokinetic interaction and overlapping serotonergic adverse-effect monitoring. (pmc.ncbi.nlm.nih.gov)
Recommended Dosing
Fluvoxamine dosing (depression/OCD labeling is shared in product labeling)
- Adult starting dose is 50 mg at bedtime. (accessdata.fda.gov)
- Dose increases are 50 mg every 4 to 7 days as tolerated to maximum therapeutic effect. (accessdata.fda.gov)
- Maximum dose is 300 mg/day. (accessdata.fda.gov)
- Daily doses over 100 mg should be divided into two doses. (accessdata.fda.gov)
Mirtazapine dosing
- Adult starting dose is 15 mg once daily, administered orally preferably in the evening prior to sleep. (dailymed.nlm.nih.gov)
- If an adequate response is not achieved, the dose may be increased to a maximum of 45 mg/day. (dailymed.nlm.nih.gov)
- Dose changes should not be made in intervals of less than 1 to 2 weeks to allow assessment of response. (dailymed.nlm.nih.gov)
Monotherapy Versus Combination Therapy
Monotherapy is the usual starting approach for depression pharmacotherapy, with combination therapy reserved for inadequate response or specific augmentation strategies.
- The combination requires heightened monitoring because fluvoxamine has clinically relevant effects on mirtazapine concentrations. (pmc.ncbi.nlm.nih.gov)
- Safety monitoring emphasis should be greatest during treatment initiation and during dose increases due to increased risk of serotonin toxicity with serotonergic polypharmacy. (accessdata.fda.gov)
Key Evidence Supporting Safety Monitoring
A pharmacokinetic interaction between fluvoxamine and mirtazapine has been reported, including a 3- to 4-fold increase in mirtazapine plasma concentrations in a small human interaction study. (pmc.ncbi.nlm.nih.gov) Serotonin syndrome risk is increased by concomitant use of serotonergic drugs and by drugs that impair serotonin metabolism. (dailymed.nlm.nih.gov)
Safety Monitoring During Combination Use
Serotonin syndrome monitoring
- All patients receiving mirtazapine should be monitored for serotonin syndrome, with immediate discontinuation of mirtazapine and concomitant serotonergic agents if serotonin syndrome symptoms occur. (dailymed.nlm.nih.gov)
- Serotonin syndrome signs include mental status changes, autonomic instability, neuromuscular abnormalities, seizures, and gastrointestinal symptoms. (dailymed.nlm.nih.gov)
- Fluvoxamine labeling advises that serotonin syndrome symptoms require discontinuation and supportive treatment, with increased risk emphasized during initiation and dose increases when other serotonergic drugs are used. (accessdata.fda.gov)
Suicidality and bipolar disorder screening
- Mirtazapine carries a boxed warning for increased risk of suicidal thoughts and behaviors and requires close monitoring for clinical worsening and emergence of suicidality. (dailymed.nlm.nih.gov)
- Bipolar disorder screening is recommended prior to starting mirtazapine. (dailymed.nlm.nih.gov)
- Fluvoxamine labeling includes suicidality monitoring and bipolar disorder screening warnings. (accessdata.fda.gov)
QTc risk and cardiovascular risk assessment
- Mirtazapine has warnings for QT prolongation and torsades de pointes, with caution recommended in patients with cardiovascular disease or family history of QT prolongation and in concomitant use of QTc-prolonging medicines. (dailymed.nlm.nih.gov)
- Increased risk has been reported particularly with overdose and in the presence of other QT risk factors or QTc-prolonging drugs. (dailymed.nlm.nih.gov)
Other clinically important adverse-effect monitoring
- Mirtazapine requires monitoring for agranulocytosis; discontinuation and close monitoring are recommended if infection symptoms occur with low white blood cell count. (dailymed.nlm.nih.gov)
- Mirtazapine requires monitoring for hyponatremia risk, with increased caution in elderly patients. (dailymed.nlm.nih.gov)
- Mirtazapine requires monitoring for activation of mania or hypomania. (dailymed.nlm.nih.gov)
Common Pitfalls to Avoid
- Abrupt discontinuation should be avoided because adverse reactions can occur on discontinuation or dose reduction, and gradual tapering is recommended rather than stopping abruptly when possible. (dailymed.nlm.nih.gov)
- Overlooking the pharmacokinetic interaction can lead to excessive mirtazapine exposure, since fluvoxamine can increase mirtazapine concentrations substantially. (pmc.ncbi.nlm.nih.gov)
- Under-monitoring during initiation and dose changes increases the risk of missing early serotonin toxicity symptoms. (accessdata.fda.gov)
Target Outcomes and Therapeutic Monitoring Goals
- Depression response monitoring should focus on improvement in depressive symptoms and on early detection of clinical worsening and suicidality, especially early in treatment and around dose adjustments. (dailymed.nlm.nih.gov)
- Ongoing safety monitoring goals should include prevention and early detection of serotonin syndrome, QTc-related adverse events in at-risk patients, hyponatremia, and activation of mania or hypomania. (dailymed.nlm.nih.gov)